EZN-2285
Term · Oncology and biomedicine · MLC-T-ONC-003105
A drug used with other drugs to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. EZN-2285 is made up of the enzyme L-asparaginase that is linked to a substance called SC-PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. EZN-2285 is a type of protein synthesis inhibitor. Also called Asparlas, calaspargase pegol, and SC-PEG E. coli L-asparaginase.
| Identifier | MLC-T-ONC-003105 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | Asparlas; calaspargase pegol; SC-PEG E |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-003105",
"term": "EZN-2285",
"field": "Oncology and biomedicine",
"definition": "A drug used with other drugs to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. EZN-2285 is made up of the enzyme L-asparaginase that is linked to a substance called SC-PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. EZN-2285 is a type of protein synthesis inhibitor. Also called Asparlas, calaspargase pegol, and SC-PEG E. coli L-asparaginase.",
"expansions": [
"Asparlas",
"calaspargase pegol",
"SC-PEG E"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/ezn-2285/"
}
Record 7,098 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.